# Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

> **NCT00708721** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Utah** · enrollment: 11 (actual)

## Conditions studied

- Cancer
- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** Clofarabine

## Key facts

- **NCT ID:** NCT00708721
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-03
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Data analysis revealed sufficient data for safety and efficacy
- **Last updated:** 2017-06-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00708721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00708721, "Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00708721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*